Clinical Trials Logo

Clinical Trial Summary

Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)) . Over the last decade, the treatments have evolved significantly but the overall survival remains limited, especially for the AML and MM patients. There's an ongoing imperative to continue in-vitro and in-vivo studies to better evaluate the anti-cancer drugs sensitivity and therefore improving the response to treatments and open new fields of application. The healthy control group will be contributing to produce some pertinent and significant data for the results of the index cases group. The investigators aim to analyze 10 differents drugs, common use in chemotherapy or immunotherapy and evaluate by 2 ways the sensitivity: first, Flow cytometry (cells apoptosis by Annexine V and propidium iodide) on fresh samples and in a second time, monitoring of the blasts in the mouse's blood after injection.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05001386
Study type Interventional
Source Hospices Civils de Lyon
Contact Charles Pr DUMONTET, PhD, MD
Phone 0478468340
Email charles.dumontet@chu-lyon.fr
Status Not yet recruiting
Phase N/A
Start date March 2022
Completion date March 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT01684150 - A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Phase 1
Terminated NCT01144780 - Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry
Enrolling by invitation NCT01728402 - Pathogenesis of Hematologic Malignancies
Completed NCT00873574 - JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders N/A
Completed NCT00186342 - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies N/A
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Terminated NCT00578539 - T-Reg Cell Kinetics, Stem Cell Transplant, REGALE N/A
Completed NCT01200498 - Study of SB939 in Subjects With Myelofibrosis Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Completed NCT00569842 - Investigation of the Cylex® ImmuKnow® Assay N/A
Completed NCT00283114 - A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Phase 1
Active, not recruiting NCT04631458 - Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis
Completed NCT01787552 - A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF Phase 1/Phase 2
Terminated NCT02766153 - Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal
Recruiting NCT02320656 - Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 N/A
Terminated NCT00943293 - Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies Phase 1
Completed NCT00038051 - Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies Phase 1
Completed NCT00061581 - Experimental Bone Marrow Transplant Protocol Phase 2